Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Dyadic International, Inc.NASDAQ: DYAI

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $1.76M rose 10.0% year over year, ahead of the -0.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 40.7% from the prior quarter. Over 3 fiscal years it compounded at -3.5% a year.

Context

  • Selling, general & admin amounted to 467.6% of revenue in FY2025, up 292.0 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $18.29M (+217.5%) for the fiscal year ending Dec 2026, a step up from the -6.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.76M+40.7% QoQ
Last fiscal yearDec 2025
$5.76M-6.1% YoY
LTMMar 2026
$5.92M-0.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.0%+91.5%+81.6 pp
1 year-6.1%+217.5%+223.6 pp
3-year CAGR-3.5%+72.4%+75.9 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
5.76M USD
Year-over-year change
-6.1%
4-year CAGR
-3.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How DYAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.4% is the 6th highest of 8, against a peer median of +44.7%.
  • Selling, general & admin amounts to 199.0% of revenue for DYAI, versus a peer median of 193.1%.
DYAI Competitors
Selling, General & Admin for DYAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANVSAnnovis Bio, Inc.LTM Mar 2026$1.3B USD+19278.2%-20.7%—
CELUCelularity Inc.LTM Dec 2025$51.27M USD-12.6%-8.1%193.1%
VERUVeru Inc.LTM Mar 2026$17.65M USD-31.3%-22.7%—
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$10.92M USD+44.7%+1065.3%—
PYPDPolyPid Ltd.LTM Mar 2026$9.7M USD+78.7%-5.6%—
RNXTRenovoRx, Inc.LTM Mar 2026$8.2M USD+53.6%+7.6%550.8%
DYAIDyadic International, Inc.LTM Mar 2026$5.92M USD-0.4%-3.5%199.0%
ATHEAlterity Therapeutics LimitedFY2025A$5.48M AUD+15.1%-0.2%100.8%
Peer median (excluding DYAI) —+44.7%-5.6%193.1%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.4M2.93M2.9M3.5M1.23M
Cost of Revenue1.94M2.12M1.98M1.19M2.32M
Gross Profit459.39K807.11K922.96K2.3M(1.09M)
Gross Margin19.1%27.5%31.8%65.8%-88.3%
Research & Development8.39M4.5M3.3M2.04M2.15M
Selling, General & Admin6.7M6.42M5.82M6.13M5.76M
Operating Expenses15.19M10.97M9.15M8.2M6.06M
Depreciation & Amortization3.49M038.42K00
EBITDA(11.14M)(10.12M)(8.15M)(5.38M)(6.91M)
EBITDA Margin-463.4%-345.2%-281.3%-154.0%-560.6%
Operating Income(14.73M)(10.17M)(8.23M)(5.9M)(7.15M)
Operating Margin-612.7%-346.9%-283.9%-168.8%-579.9%
Interest Income51.7K180.42K416.69K456.99K284.09K
Interest Expense000427.97K455.9K
Other Income / Expenses1.66M430.42K1.43M91.66K(218.71K)
Income Before Tax(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Pre-Tax Margin-543.7%-332.2%-234.4%-166.2%-597.6%
Income Tax Expense00000
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Net Margin-543.7%-332.2%-234.4%-166.2%-597.6%
EPS (Basic)(0.47)(0.34)(0.24)(0.20)(0.23)
EPS (Diluted)(0.47)(0.34)(0.24)(0.20)(0.23)
Weighted Avg Shares27.84M28.36M28.8M29.32M32.62M
Weighted Avg Shares (Diluted)27.84M28.36M28.8M29.32M32.62M

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.